Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sen. Cory Booker. Photo: Scott Olson/Getty Images

Some of the left's skepticism of Sen. Cory Booker (D-N.J.) stems from his reputation as a friend of pharma, and he's trying to change that reputation as he runs for president.

Why it matters: As Democrats figure out what and who they want in 2020, a whole lot of the process revolves around health care — not just in the potential litmus test of Medicare for All, but also drug pricing, the Affordable Care Act and how to balance all 3 of those issues.

Booker's pro-pharma reputation has 3 big components: the industry's presence in New Jersey; its contributions to his past campaigns; and his 2017 vote against a non-binding measure to approve of importing drugs from Canada.

Yes, but: He's changed his tune ahead of 2020, STAT notes. Booker has taken a harsher tone toward pharma, even threatening to roll back their patent protections, and said he would stop taking the industry's campaign contributions.

What he's saying: "I live in Newark, a low-income community where people work for pharmaceutical companies," Booker told STAT. "They might be the lab assistant, they might be the secretary, and they value those jobs. And even they know that we can have fair pricing and still have thriving companies. This is not an either-or. And right now we have practices going on that are abusing this nation and constituents of mine."

Go deeper: Pharma critics turn their fire on a Democrat

Go deeper

Cyber war scales up with new Microsoft hack

Illustration: Aïda Amer/Axios

Last week's revelation of a new cyberattack on thousands of small businesses and organizations, on top of last year's SolarWinds hack, shows we've entered a new era of mass-scale cyber war.

Why it matters: In a world that's dependent on interlocking digital systems, there's no escaping today's cyber conflicts. We're all potential victims even if we're not participants.

Miriam Kramer, author of Space
27 mins ago - Science

Spaceflight contests and our future in orbit

Illustration: Aïda Amer/Axios

Wealthy private citizens are increasingly becoming the arbiters of who can go to space — and some of them want to bring the average person along for the ride.

Why it matters: Space is being opened up to people who wouldn't have had the prospect of flying there even five years ago, but these types of missions have far-reaching implications for who determines who gets to make use of space and for what.

1 hour ago - Health

Axios-Ipsos poll: America looks for the exits after a year of COVID

Data: Axios/Ipsos poll; Chart: Danielle Alberti/Axios

A year after the coronavirus abruptly shut down much of the country, Americans are watching for a clear signal of when the pandemic will be over — and most won't be ready to ditch the masks and social distancing until they get it, according to the latest installment of the Axios/Ipsos Coronavirus Index.

The big picture: The poll found that more Americans are expecting the outbreak to be over sooner rather than later, as vaccinations ramp up throughout the country — but that very few are ready to end the precautions that have upended their lives.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!